La vendita allo scoperto per Processa Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Processa Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Processa Pharma (NASDAQ:PCSA) Azioni, Report sulle vendite allo scoperto

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

JP Morgan analyst Andrew Steinerman maintains Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) with a Neutral and raises the price target from $15 to $16.

News

Price Target

Analyst Ratings

VSTS

JP Morgan Maintains Neutral on Vestis, Raises Price Target to $16

Elon Musk and <a href="https://www.benzinga.com/startups/24/11/42038767/im-one-of-you-how-anti-woke-warrior-vivek-ramaswamy-became-a-billionaire-at-only-38">Vivek Ramaswamy</a> have been appointed to lead a new <a href="https://www.benzinga.com/news/24/11/42026862/musk-and-ramaswamy-seek-spending-cut-wins-where-others-failed">government-efficiency commission</a> created by Donald Trump. The stated goal is to cut government spending and one approach being considered involves reducing or eliminating certain federal agencies.&nbsp;
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
As Business Insider reports, while Ramaswamy expects to &#8220;delete&#8221; whole government agencies, Musk emphasized that the plan is not to leave people without support but to streamline the federal workforce in areas they consider &#8220;bloated.&#8221; He has mentioned the possibility of offering severance packages of up to two years&#8217; pay to those affected.
According to official government data, 2,278,730 Americans worked for the federal government as of March 2024. Some departments are significantly larger than others. For example, the <a href="https://www.benzinga.com/24/11/42021130/with-doug-collins-as-va-leader-whats-next-for-cannabis-and-psychedelics-in-veterans-healthcare">Department of Veterans Affairs</a> employs nearly half a million people, while the Department of Education has just over 4,000 employees. Within the Treasury Department, most of the 100,000+ employees work for the Internal Revenue Service (IRS).
Departments with more than 100,000 employees:
<ul>
<li>Department of Veterans Affairs (486,522)</li>
<li>Department of Homeland Security (222,539)</li>
<li>Department of the Army (221,037)</li>
<li>Department of the Navy (216,537) </li>
<li>Department of the Air Force (168,505)</li>
<li>Department of Defense (156,803)</li>
<li>Department of Justice (116,614)</li>
<li>Department of the Treasury (108,869)</li>
</ul>
See Also: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Many federal workers earn competitive salaries, with most departments offering six-figure averages. The Department of Education <a href="https://www.benzinga.com/markets/equities/24/09/40963177/us-department-of-energy-to-invest-3b-in-battery-production">and Energy</a> tend to have the highest average salaries among government agencies, at $144,561 and $143,486, respectively.
Departments with the highest average salary:
<ul>
<li>Department of Education ($144,561)</li>
<li>Department of Energy ($143,486)</li>
<li>Department of Transportation ($139,474)</li>
<li>Department of Housing and Urban Development ($134,503)</li>
<li>Department of State ($132,587)</li>
<li>Department of Health and Human Services ($130,117)</li>
</ul>
This is not the first time a commission like this has been formed. According to Business Insider, Ronald Reagan had the Grace Commission in the 1980s, which aimed to find waste and inefficiencies in federal spending. However, it is important to note that Musk and Ramaswamy&#8217;s new effort does not have the authority to make these changes on its own – it will need Congress to back its recommendations.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are very grateful to the thousands of Americans who have expressed interest in helping us at DOGE. We don't need more part-time idea generators. We need super high-IQ small-government revolutionaries willing to work 80+ hours per week on unglamorous cost-cutting. If that's…
&mdash; Department of Government Efficiency (@DOGE) <a href="https://twitter.com/DOGE/status/1857076831104434289?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
To fulfill their goals, <a href="https://www.benzinga.com/news/24/11/41998717/elon-musk-and-vivek-ramaswamy-are-looking-for-high-iq-small-government-revolutionaries-who-are-willing-to-put-in-80-hours-at-doge">Musk and Ramaswamy are seeking</a> &#8220;super high-iQ small-government revolutionaries&#8221; to help reduce federal inefficiencies under President-elect Donald Trump. DOGE&#8217;s official account on X posted a call for applicants willing to work 80+ hours a week to streamline government spending and cut bureaucracy. Interested candidates are encouraged to DM their CVs, with Musk and Ramaswamy supposedly personally reviewing the top 1% of applicants.
While Musk and Ramaswamy&#8217;s approach aims to make the government &#8220;leaner&#8221; and potentially more efficient, there are significant concerns regarding the impact of such drastic cuts. Eliminating entire agencies could result in disruptions to essential public services, affecting everything from health care to education to veterans&#8217; support. The loss of federal jobs could also have a broader economic impact, particularly in regions where government employment forms a significant part of the local economy.&nbsp;
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>

With Musk And Ramaswamy Preparing To Slash Entire Government Agencies, Here's Which Departments Employ The Most Americans And Their Salaries

In the current session, the stock is trading at $145.85, after a 0.73% spike. Over the past month, Cava Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) stock increased by 7.08%, and in the past year, by 333.82%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732288513_0.png" alt="Past Year Chart" />

<h3>Cava Group P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cava Group has a better P/E ratio of 353.17 than the aggregate P/E ratio of 69.6 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that Cava Group Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732288513_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

CAVA

Price Over Earnings Overview: Cava Group

JP Morgan analyst Matthew Boss maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Neutral and raises the price target from $26 to $28.

JP Morgan Maintains Neutral on Gap, Raises Price Target to $28

JP Morgan analyst Matthew Boss maintains Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) with a Overweight and raises the price target from $171 to $173.

ROST

JP Morgan Maintains Overweight on Ross Stores, Raises Price Target to $173

Keybanc analyst Jason Celino maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $68 to $85.

PCOR

Keybanc Maintains Overweight on Procore Technologies, Raises Price Target to $85

Stifel analyst Simon Yarmak upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Hold to Buy and raises the price target from $14.75 to $15.

Upgrades

Stifel Upgrades Pebblebrook Hotel to Buy, Raises Price Target to $15

JP Morgan analyst Alexei Gogolev maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $75 to $85.

JP Morgan Maintains Overweight on Procore Technologies, Raises Price Target to $85

Stifel analyst Simon Yarmak downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Buy to Hold and lowers the price target from $10.75 to $10.25.

Downgrades

Stifel Downgrades Diamondrock Hospitality to Hold, Lowers Price Target to $10.25

DIRECTV announced Friday it would terminate its agreement to acquire EchoStar Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) <a href="https://www.prnewswire.com/news-releases/directv-announces-termination-of-agreement-to-acquire-echostars-video-distribution-business-302313823.html" target="_blank" rel="noreferrer noopener">video distribution business, DISH DBS</a>. 
The decision follows DISH DBS noteholders&#8217; refusal to accept EchoStar&#8217;s proposed Exchange Debt Offer Terms, a critical condition for the deal to proceed. 
EchoStar stock tanked after the update.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42137930/boeing-secures-238-billion-deal-for-advanced-kc-46a-tankers" rel="noreferrer noopener">Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers</a>
DirecTV CEO Bill Morrow said &#8220;the proposed Exchange Terms were necessary to protect DirecTV&#8217;s balance sheet and our operational flexibility.&#8221;
DirecTV <a target="_blank" href="https://www.benzinga.com/news/24/09/41094002/echostar-stock-dives-on-directv-dish-deal-the-details" rel="noreferrer noopener">agreed to acquire</a> EchoStar&#8217;s video business for $1 and assume Dish DBS&#8217;s net debt. The companies launched an exchange offer for five Dish DBS note series totaling approximately $9.75 billion in face value.
DirecTV plans to continue investing in next-generation streaming technologies and developing new packaging options integrating live TV with direct-to-consumer platforms. The company aims to provide customers with enhanced flexibility and tailored content options that align with evolving viewer preferences.
The termination of the DISH acquisition does not impact TPG&#8217;s plan to purchase the remaining 70% stake in DirecTV from AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), which remains scheduled to close in the second half of 2025. This strategic move is expected to strengthen DirecTV&#8217;s market positioning further.
EchoStar reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41905346/echostar-q3-earnings-and-sales-falter-but-gains-ground-with-sling-tv-subscribers" rel="noreferrer noopener">third-quarter loss</a> of 52 cents per share, missing analysts&#8217; expected loss of 37 cents. Revenue came in at $3.89 billion, a 5.3%, falling short of the $3.909 billion consensus estimate.
During the quarter, net Pay-TV subscribers declined by 43,000, while Sling TV added 145,000 new users. The company closed the period with 8.03 million Pay-TV subscribers, including 5.89 million for DISH TV and 2.14 million for Sling TV.
Price Action: EchoStar&#8217;s shares are trading lower by 3% to $22.86 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137039/disney-takes-on-netflix-with-high-impact-originals-in-asia" target="_blank" rel="noreferrer noopener">Disney Takes on Netflix With High-Impact Originals in Asia</a></li>
</ul>
Image via DirecTV

SATS

EchoStar Shares Sink As DirecTV Terminates Acquisition Agreement

Keybanc analyst Jackson Ader maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $345 to $395.

CRWD

Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $395

JP Morgan analyst Jeremy Tonet maintains Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Neutral and raises the price target from C$62 to C$63.

TSX:PPL

JP Morgan Maintains Neutral on Pembina Pipeline, Raises Price Target to C$63

Stifel analyst Selman Akyol maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Hold and lowers the price target from $70 to $69.

Stifel Maintains Hold on Spire, Lowers Price Target to $69

Stifel analyst Adam Borg maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Buy and raises the price target from $70 to $84.

Stifel Maintains Buy on Procore Technologies, Raises Price Target to $84

Stifel analyst Matthew Sheerin maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Buy and raises the price target from $140 to $145.

NTAP

Stifel Maintains Buy on NetApp, Raises Price Target to $145

Aecom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) shares are trading up Friday, after gaining <a href="https://www.benzinga.com/quote/ACM">around 5% during the week</a>.
The company &#8220;high-graded its portfolio" by increasingly focusing on larger and more complex design projects, where it has the greatest competitive advantage, and is moving further towards program management and advisory, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/650419668345120001a2ee65/adam-bubes">Analyst Adam Bubes</a> initiated coverage of Aecom with a Buy rating and price target of $130.
The Aecom Thesis: Engineering News-Record's market data shows that the company has industry-leading design market share in its largest end markets, Bubes said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Bubes noted that Aecom secured the second-highest position in program management, increasing its market share from 6.6% of the top 50 program managers since 2021 to around 11% today.
"We forecast a 6% total company organic growth CAGR through 2027 driven by AECOM's accelerating win rates, double-digit program management and advisory growth, and solid underlying end market trends," the analyst wrote.
Since 2020, Aecom has "divested its self-perform at-risk construction businesses, exited low return countries, and shifted resources to larger and more complex projects," Bubes said. The company's high-graded portfolio is now "driving higher returns at lower risk," he added.
ACM Price Action: Shares of Aecom were up 2.62% at $115.51 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069454/aecom-reports-q4-results-joins-incyte-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session">Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday&#8217;s Pre-Market Session</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Long Ideas

Initiation

Movers

Trading Ideas

Aecom Drives 'Higher Returns At Lower Risk,' Says Bullish Analyst

Stifel analyst Rick Wise reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Buy and raises the price target from $170 to $190.

Reiteration

MASI

Stifel Reiterates Buy on Masimo, Raises Price Target to $190

On November 21, a recent SEC filing unveiled that Resource Group International Ltd, Board Member at IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) made an insider sell.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001720420/000183988224040494//Archives/edgar/data/1720420/000183988224040494/0001839882-24-040494-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Ltd sold 3,562,341 shares of IBEX. The total transaction value is $70,000,000.
IBEX shares are trading down 0.0% at $21.13 at the time of this writing on Friday morning.
<h3>Discovering IBEX: A Closer Look</h3>
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
<h3>Unraveling the Financial Story of IBEX</h3>
Revenue Growth: IBEX's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.1%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 30.59%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, IBEX exhibits below-average bottom-line performance with a current EPS of 0.45.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.39, IBEX adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: IBEX's P/E ratio of 11.24 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.74 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): IBEX's EV/EBITDA ratio, lower than industry averages at 4.64, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001720420">Check Out The Full List Of IBEX's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

IBEX

Insider Decision: Resource Group International Ltd Offloads $70.00M Worth Of IBEX Stock

Disclosed on November 21, Patrick J McEnany, Director at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000457//Archives/edgar/data/1369568/000116169724000457/0001161697-24-000457-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, McEnany sold 170,845 shares of Catalyst Pharmaceuticals. The total transaction value is $3,627,258.
Monitoring the market, Catalyst Pharmaceuticals's shares up by 1.23% at $21.38 during Friday's morning.
<h3>Discovering Catalyst Pharmaceuticals: A Closer Look</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Breaking Down Catalyst Pharmaceuticals's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Catalyst Pharmaceuticals's P/E ratio of 17.9 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 5.59 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 9.84, Catalyst Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPRX

Catalyst Pharmaceuticals Insider Trades Send A Signal

Revealing a significant insider sell on November 21, Michael Gianoni, President and CEO at Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>), as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001280058/000157856324000460//Archives/edgar/data/1280058/000157856324000460/0001578563-24-000460-index.htm">U.S. Securities and Exchange Commission</a> on Thursday outlined that Gianoni executed a sale of 28,571 shares of Blackbaud with a total value of $2,370,648.
Monitoring the market, Blackbaud's shares up by 0.01% at $85.38 during Friday's morning.
<h3>Get to Know Blackbaud Better</h3>
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&amp;A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
<h3>Blackbaud's Economic Impact: An Analysis</h3>
Revenue Growth: Blackbaud displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 55.53%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Blackbaud exhibits below-average bottom-line performance with a current EPS of 0.41.
</li>
</ul>
Debt Management: Blackbaud's debt-to-equity ratio surpasses industry norms, standing at 1.9. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: Blackbaud's current Price to Earnings (P/E) ratio of 84.52 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.97 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Blackbaud's EV/EBITDA ratio at 20.47 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001280058">Check Out The Full List Of Blackbaud's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLKB

Michael Gianoni Executes Sell Order: Offloads $2.37M In Blackbaud Stock

FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is rising higher on Tuesday after the company <a href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-fda-clearance-120000203.html">posted an update</a> from the Food and Drug Administration (FDA).



The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company&rsquo;s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.



With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.



David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.




&ldquo;We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.&rdquo;




<h2>PCSA Stock Movement Today</h2>



With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company&rsquo;s daily average trading volume of about 90,000 shares.



PCSA stock is up 29.4% as of Tuesday morning.



Investors seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Delta&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dal-stock-quote/">DAL</a>) and SoFi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>



<li><a href="https://investorplace.com/2024/07/dal-stock-delta-wants-crowdstrike-to-pay-up-for-flight-delays-caused-by-outage/">DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</a></li>



<li><a href="https://investorplace.com/2024/07/sofi-stock-sofi-just-raised-its-profit-guidance-again-whats-going-on/">SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What&rsquo;s Going On?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is still rallying higher as a bankruptcy filing has introduced an immense amount of volatility to the online education platform company&rsquo;s shares.



Today&rsquo;s movement has TWOU stock rallying 15.5% as of Tuesday morning. That comes with more than 31 million shares changing hands. For the record, its daily average trading volume is about 2.5 million shares.



The rally today <a href="https://investorplace.com/2024/07/2u-twou-stock-pops-more-than-100-despite-bankruptcy-filing/">follows a surge yesterday</a> that saw the stock jump as more than 100% higher during normal trading hours. It is worth noting that these rallies come after the stock suffered a roughly 60% drop when news of its bankruptcy broke.



<h2>What&rsquo;s Next for 2U Stock?</h2>



2U is using this bankruptcy to <a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">restructure its debt</a> via deals with lenders. This has the company continuing operations throughout the process. It expects to exit bankruptcy by the end of September.



It&rsquo;s also unclear how this bankruptcy filing will affect TWOU stock. While the company is only using it for restructuring, it could cause problems for its listing on the Nasdaq Exchange.



Also, all of this volatility makes TWOU stock a bit of a risky investment. Traders will want to keep that in mind before taking a stake in the company.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market stories that traders need to know about on Tuesday! That includes warnings of a potential market crash, why Processa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is up today and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

2U (TWOU) Stock Continues to Surge in Bankruptcy Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) just reported results for the second quarter of 2024.<ul><li>Processa Pharma reported earnings per share of -$1.01. This was below the analyst estimate for EPS of -98 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pcsa-stock-earnings-processa-pharma-for-q2-of-2024/">PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), H...

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)

Processa Pharmaceuticals reports GAAP EPS of -$1.01

Processa stock rallies 35% post-market on Phase 2 study update

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals (PCSA – Research Report), retaining the price target o...

Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap

Processa Pharmaceuticals GAAP EPS of -$1.03

Processa Pharmaceuticals, Inc. ( ($PCSA) ) has released its Q3 earnings. Here is a breakdown of the information Processa Pharmaceuticals, Inc. pres...

Processa Pharmaceuticals Reports Q3 2024 Financial Results

PCSA

PSNL

SOFI

TSLA

TWOU

Press Releases

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Comments

Processa Pharma

Vendite allo scoperto

Processa Pharma (NASDAQ:PCSA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO